SecBot SecBot
6-K ·Filed Nov 3, 2026

NVO

NOVO NORDISK A S
NEUTRAL
Impact 2/10
Horizonimmediate Processed13d 16h ago SEC0001171843-26-007060
Notable filing: 6-K
Actionable Insight • Neutral

The repurchase program continues on schedule with approximately DKK 3.4 billion remaining under the current tranche. Monitor for any changes in the pace of buybacks or completion of the program.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$40.19
T+0 close · Nov 3, 2026 · via day close
Latest settled
+1.27%
T+5 · $40.70 · next T+20 in 15d
Vs SPY
+1.86%
α at T+5
Latest observation
+4.82%
T+9 · FF3 residual α
  1. T+0 · Nov 3 $40.19entry
  2. T+1 · 13d ago +4.95%α +3.30% · $42.18
  3. T+5 · 7d ago +1.27%α +1.86% · $40.70
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Novo Nordisk filed a routine 6-K updating its ongoing share repurchase program, reporting the repurchase of 1.44 million B shares for approximately DKK 377 million during the week ended November 2, 2026. The filing is a standard periodic update with no material new information about the company's financial performance or outlook.

Key Facts

  • Novo Nordisk repurchased 1,440,000 B shares from October 26 to November 2, 2026, at an average price of DKK 261.85 per share, for a total transaction value of approximately DKK 377 million.
  • Since the program's initiation on May 6, 2026, the company has repurchased 26,955,000 B shares for a total of DKK 7,764,364,812.
  • The overall share repurchase program authorizes up to DKK 15 billion over a 12-month period beginning February 4, 2026; as of November 2, 2026, Novo Nordisk has repurchased 41,714,179 B shares at an average price of DKK 277.23 per share, totaling DKK 11,564,364,801.
  • Novo Nordisk holds 55,754,876 B shares as treasury shares, representing 1.2% of the total share capital of 4,465,000,000 shares.

Financial Impact

No material financial impact; the filing reports routine share repurchase transactions under a previously announced program.

dilution

Risk Factors

  • No new risks identified; this is a routine update on an ongoing capital return program.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
28% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-007060
Document: 0001171843-26-007060-index-headers.html0001171843-26-007060
Document: 0001171843-26-007060-index.html0001171843-26-007060
Document: 0001171843-26-007060.txt0001171843-26-007060
Earnings Context (Synthetic; results releases only)0001171843-26-007060

Track record

43 reports on NVO

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +23.56% at T+60 after the Jul 28, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Neutral 2/10 Entry $41.89 Now $41.60 −0.69% settles Dec 15
  2. Nov 13, 20264d ago Court Ruling Neutral 3/10 Entry $42.01 Now $41.60 −0.98% settles Dec 15
  3. Nov 13, 20264d ago Court Ruling Neutral 1/10 Entry $42.01 Now $41.60 −0.98% settles Dec 15
  4. Nov 9, 20267d ago 6-K Neutral 2/10 Entry $41.38 Now $41.60 +0.53% settles Dec 8
  5. Nov 5, 202611d ago Institutional Cluster Neutral 2/10 Entry $40.30 Now $41.60 +3.23% settles Dec 4
  6. Nov 5, 202611d ago 6-K Neutral 2/10 Entry $40.30 Now $41.60 +3.23% settles Dec 4
  7. Nov 4, 202612d ago 6-K Bullish 6/10 Entry $42.18 Now $41.60 −1.38% settles Dec 3
  8. Nov 3, 202613d ago 6-K Neutral 2/10 Viewing Entry $40.19 Now $41.60 +3.51% settles Dec 2
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $39.13 Now $41.60 +6.31% settles Nov 23
  10. Oct 26, 202622d ago Court Ruling Neutral 4/10 Entry $38.67 Now $41.60 +7.58% settles Nov 24
Showing 10 of 43

US Market Status

Market Closed · Opens in 5h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026